Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Kori Wallace"'
Autor:
Yinuo Pang, Ronilda D'Cunha, Insa Winzenborg, Geertruida Veldman, Valerie Pivorunas, Kori Wallace
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract Risankizumab is a high‐affinity neutralizing anti‐interleukin (IL)‐23 monoclonal antibody marketed in over 40 countries across the globe to treat several inflammatory diseases, such as plaque psoriasis (PsO), psoriatic arthritis (PsA),
Externí odkaz:
https://doaj.org/article/2606d68cf87141a79c6057e690d31f3c
Autor:
Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson
Publikováno v:
Intestinal Research, Vol 14, Iss 2, Pp 152-163 (2016)
Background/AimsThis was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).MethodsThirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450
Externí odkaz:
https://doaj.org/article/8bca98f05c004c12a083df89bf50d6f6
Autor:
Edward V. Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace, Sujani Nannapaneni, Ji Zhou, Rachel Byrne, Kristina Kligys, Yinuo Pang, Xiaomei Liao, Jasmina Kalabic, Marla Dubinsky
Publikováno v:
Advances in Therapy. 40:2311-2325
Autor:
Laurent Peyrin‐Biroulet, Subrata Ghosh, Scott D. Lee, Wan‐Ju Lee, Jenny Griffith, Kori Wallace, Sofie Berg, Xiaomei Liao, Julian Panes, Edward V. Loftus, Edouard Louis
Publikováno v:
Alimentary Pharmacology & Therapeutics. 57:496-508
Crohn's disease has a substantial negative impact on health-related quality of life (HRQoL).To examine the effects of risankizumab on HRQoL in Crohn's disease METHODS: We analysed data from patients with Crohn's disease from 12-week induction trials
Autor:
Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G Feagan, Tadakazu Hisamatsu, Allen Lim, James O Lindsay, Edward V Loftus, Julián Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T Rubin, William J Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D'Haens
Publikováno v:
The Lancet, 399(10340), 2031-2046. Elsevier Limited
Background: There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e49b5f7038521294b69cf744c4fbd1
https://pure.amc.nl/en/publications/risankizumab-as-maintenance-therapy-for-moderately-to-severely-active-crohns-disease(a545e349-2239-4e02-8ea2-d744c64bcc91).html
https://pure.amc.nl/en/publications/risankizumab-as-maintenance-therapy-for-moderately-to-severely-active-crohns-disease(a545e349-2239-4e02-8ea2-d744c64bcc91).html
Autor:
Geert D’Haens, Remo Panaccione, Julián Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, W Rachel Duan, Kristina Kligys, Marla Dubinsky
Publikováno v:
Gastroenterología y Hepatología. 46:S149
Autor:
Geert D’Haens, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Peter Bossuyt, Silvio Danese, Ezequiel Neimark, Alexandra Song, Xiaomei Liao, Kori Wallace, Javier Zambrano, W Rachel Duan, Kristina Kligys, Marla Dubinsky
Publikováno v:
American Journal of Gastroenterology. 117:e497-e498
Autor:
Sofie Berg, Kori Wallace, L Peyrin-Biroulet, J Griffith, Scott D. Lee, Edouard Louis, Subrata Ghosh, Edward V. Loftus
Publikováno v:
Journal of Crohn's and Colitis. 15:S119-S121
Background Risankizumab (RZB), an IL-23 inhibitor, is being investigated for Crohn’s disease (CD). MOTIVATE (NCT03105128) and ADVANCE (NCT03104413) were two double-blind, randomised, placebo (PBO)-controlled phase 3 trials evaluating the efficacy a
Autor:
Marc Ferrante, Arthur Kaser, Geert R. D'Haens, Wan-Ju Lee, Julián Panés, Xiaomei Liao, Olivier Dewit, Brian G. Feagan, Filip Baert, Jasmina Kalabic, W. Rachel Duan, Kori Wallace, Yinuo Pang, Dawn Gustafson, Edouard Louis
Publikováno v:
Journal of Crohn's & colitis, 15(12), 2001-2010. Elsevier
Journal of Crohn's & colitis, Vol. 15, no.12, p. 2001-2010 (2021)
Journal of Crohn's & Colitis
Journal of Crohn's & colitis, Vol. 15, no.12, p. 2001-2010 (2021)
Journal of Crohn's & Colitis
Background and Aims Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn’s disease. This open-label extension investigated the long-term safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e418780af15ef3e836bc2ac0db175f7
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-risankizumab-treatment-in-patients-with-crohns-disease(2efdb272-1af3-47e5-a541-ad43af36fa8f).html
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-risankizumab-treatment-in-patients-with-crohns-disease(2efdb272-1af3-47e5-a541-ad43af36fa8f).html
Autor:
Geert D'Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G Feagan, Tadakazu Hisamatsu, Allen Lim, James O Lindsay, Edward V Loftus, Julian Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T Rubin, William J Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Marc Ferrante
Publikováno v:
The Lancet, 399(10340), 2015-2030. Elsevier Limited
Background: Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease. Methods: ADVANCE and MOTIVATE were randomised, double-masked, p